Physician profile
John Still
NPI 1689203796
$2,741.50
in general payments reported to CMS, 2019-2025
20 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $265 · 2024: $1,068 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.03 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $437.27 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $272.28 | 2023-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $218.49 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $183.58 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.69 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $118.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $110.73 | 2023-2025 | |
| Astellas Pharma US INC | $100.24 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $87.87 | 2023-2025 | Keveyis |
| Abiomed | $48.17 | 2024-2025 | Impella |
| Otsuka America Pharmaceutical, INC. | $40.91 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $36.28 | 2024-2025 | Arexvy, Shingrix |
| Seqirus USA INC | $32.27 | 2024 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $27.62 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $25.52 | 2024 | |
| Paratek Pharmaceuticals, INC. | $23.20 | 2025 | Nuzyra |
| Sumitomo Pharma America, INC. | $17.62 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.69 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $15.31 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Still listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.